Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 01, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Docetaxel Injection USP, 20 mg/2 mL (10 mg/mL) Single-Dose Vial, and 80 mg/8 mL (10 mg/mL) and 160 mg/16 mL (10 mg/mL) Multiple-Dose Vials.".